Abstract
Introduction/BackgroundIn platinum-sensitive recurrent ovarian cancer (PSROC) patients, PARP inhibitors (PARPis) represent the first choice for maintenance therapy (if PARPis naïve). Several real word data suggested that a normalized CA125 at...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have